← Back to Patent Explorer
US4895845A Expired / Lapsed US ⏱️ 0.0 years remaining

Method of assisting weight loss

Assignee: Individual
•
Filing: 1986-09-15
•
Granted: 1990-01-23
•
Expires: 2006-09-15
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method of assisting weight loss involving the combined administration of a rauwolfia alkaloid and at least one antidepressant, selected from the groups consisting of aminoazoles, phenoxyphenylpropylamines, and aminopropiophenones, in a daily regimen with the optional co-administration of one or more sympathomimetic anorexic agents. In a typical embodiment of this method, reserpine and trazodone are administered in a daily regimen with diethylpropion, fenfluramine or both diethylpropion and fenfluramine.

Inventors

  • 👤 John C. Seed

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-03 18:54
CPC Classifications
A; A61; A61K; A61K45/00; A61K45/06; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/475

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 63 words
A method of assisting weight loss in a human in need thereof which comprises administering to said human, over a sustained period of time, both a rauwolfia alkaloid in the form of reserpine, and at least one antidepressant selected from the group consisting of trazodone, bupropion and fluoxetine in an administration regimen sufficient to supply effective daily dosages thereof for assisting weight loss.
Claim 2
Independent Claim 63 words
A method of assisting weight loss in a human in need thereof which comprises administering to said human, over a sustained period of time, both a rauwolfia alkaloid in the form of reserpine, and at least one antidepressant selected from the group consisting of trazodone, bupropion and fluoxetine in an administration regimen sufficient to supply effective daily dosages thereof for assisting weight loss.
Claim 3
Dependent Claim 18 words
The method of claim 1 wherein said antidepressant is trazodone and both reserpine and trazodone are administered concomitantly.
Claim 4
Dependent Claim 25 words
The method of claim 1 wherein the daily dosage of reserpine is between about 0.001 and about 0.01 milligram per kilogram of human body weight.
Claim 5
Dependent Claim 30 words
The method of claim 1 wherein said antidepressant is trazodone and the daily dosage of trazodone is between about 0.1 and about 6.0 milligram per kilogram of human body weight.
Claim 6
Dependent Claim 18 words
The method of claim 1 wherein said antidepressant is fluoxetine and both reserpine and fluoxetine are administered concomitantly.
Claim 7
Dependent Claim 25 words
The method of claim 1 wherein the daily dosage of reserpine is between about 0.001 and about 0.01 milligram per kilogram of human body weight.
Claim 8
Dependent Claim 30 words
The method of claim 1 wherein said antidepressant is fluoxetine and the daily dosage of fluoxetine is between about 0.1 and about 1.5 milligram per kilogram of human body weight.
Claim 9
Dependent Claim 39 words
The method of claim 1 wherein the rauwolfia alkaloid is reserpine, and both trazodone and fluoxetine are administered, said reserpine, trazodone, and fluoxetine being administered in a regimen sufficient to supply effective daily dosages thereof for assisting weight loss.
Claim 10
Dependent Claim 40 words
The method of claim 1 wherein the rauwolfia alkaloid is reserpine, and trazodone, bupropion, and fluoxetine are administered, said reserpine, trazodone, bupropion and fluoxetine being administered in a regimen sufficient to supply effective daily dosages thereof for assisting weight loss.
Claim 11
Dependent Claim 39 words
The method of claim 1 wherein the rauwolfia alkaloid is reserpine, and both trazodone and bupropion are administered, said reserpine, trazodone, and bupropion being administered in a regimen sufficient to supply effective daily dosages thereof for assisting weight loss.

References Cited (Backward Citations)

DE2048926A1 Cited
US4626549A Cited
US4310524A Cited
US4442113A Cited
US4525359A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1993-01-22 1993-07-24 1994-01-23 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1997-01-22 1997-07-24 1998-01-23 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2001-01-22 2001-07-24 2002-01-23 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag